Efficacy and toxicity of Iodine-125 seed implantation for lymph node recurrence secondary to esophageal cancer after radiotherapy : a multicenter retrospective study
© 2023. The Author(s)..
BACKGROUND/OBJECTIVE: This multicenter study aimed to explore the efficacy and toxicity of radioactive Iodine-125 seed implantation for lymph node recurrence in patients with esophageal cancer after external radiotherapy.
METHODS: Clinical data of eligible patients from 5 centers in China were retrospectively reviewed. A total of 126 patients between January 2016 and March 2019 were included. The median interval between previous radiotherapy and radioactive Iodine-125 seed implantation was calculated. The target volume was 2.1-128.1 cm3 (median, 22.2 cm3) and the median postoperative D90 is 120.6 Gy (range, 101.7-192). Short-term efficacy of tumor response, the long-term efficacy of local progression-free survival (LRFS) and overall survival (OS), and treatment-related toxicity were reported.
RESULTS: For tumor response, 37 (29.4%), 51 (40.5%), 14 (11.1%), and 24 (19.0%) patients achieved complete response, partial response, stable disease and progressive disease, respectively. The 1-, 2- and 3-year LPFS and OS rates were 48.8%, 23.0% and 15.9%, and 80.2%, 38.8%, and 24.5%, respectively. Multivariate analysis identified Karnofsky performance status (P = 0.041) and tumor response (P = 0.049) as independent prognostic factors for LPFS; initial tumor stage (P = 0.034), lesion volume (P = 0.017), and tumor response (P = 0.004) as independent prognostic factors for OS. In total, 77 (61.1%) patients suffered from skin reactions and the incidence of grade 3-5 skin toxicity was 5.6% (7/126).
CONCLUSION: Radioactive Iodine-125 seed implantation seems efficient with acceptable toxicity for the treatment of lymph node recurrence secondary to esophageal cancer. A head-to-head study is needed to further evaluate the survival benefit.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2023 |
|---|---|
| Erschienen: |
2023 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:18 |
|---|---|
| Enthalten in: |
Radiation oncology (London, England) - 18(2023), 1 vom: 26. Jan., Seite 18 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Wu, Lirong [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
Esophageal cancer |
|---|
| Anmerkungen: |
Date Completed 27.01.2023 Date Revised 02.02.2023 published: Electronic Citation Status MEDLINE |
|---|
| doi: |
10.1186/s13014-022-02196-y |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM352086769 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM352086769 | ||
| 003 | DE-627 | ||
| 005 | 20231226052920.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231226s2023 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1186/s13014-022-02196-y |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1173.xml |
| 035 | |a (DE-627)NLM352086769 | ||
| 035 | |a (NLM)36698157 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Wu, Lirong |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Efficacy and toxicity of Iodine-125 seed implantation for lymph node recurrence secondary to esophageal cancer after radiotherapy |b a multicenter retrospective study |
| 264 | 1 | |c 2023 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 27.01.2023 | ||
| 500 | |a Date Revised 02.02.2023 | ||
| 500 | |a published: Electronic | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a © 2023. The Author(s). | ||
| 520 | |a BACKGROUND/OBJECTIVE: This multicenter study aimed to explore the efficacy and toxicity of radioactive Iodine-125 seed implantation for lymph node recurrence in patients with esophageal cancer after external radiotherapy | ||
| 520 | |a METHODS: Clinical data of eligible patients from 5 centers in China were retrospectively reviewed. A total of 126 patients between January 2016 and March 2019 were included. The median interval between previous radiotherapy and radioactive Iodine-125 seed implantation was calculated. The target volume was 2.1-128.1 cm3 (median, 22.2 cm3) and the median postoperative D90 is 120.6 Gy (range, 101.7-192). Short-term efficacy of tumor response, the long-term efficacy of local progression-free survival (LRFS) and overall survival (OS), and treatment-related toxicity were reported | ||
| 520 | |a RESULTS: For tumor response, 37 (29.4%), 51 (40.5%), 14 (11.1%), and 24 (19.0%) patients achieved complete response, partial response, stable disease and progressive disease, respectively. The 1-, 2- and 3-year LPFS and OS rates were 48.8%, 23.0% and 15.9%, and 80.2%, 38.8%, and 24.5%, respectively. Multivariate analysis identified Karnofsky performance status (P = 0.041) and tumor response (P = 0.049) as independent prognostic factors for LPFS; initial tumor stage (P = 0.034), lesion volume (P = 0.017), and tumor response (P = 0.004) as independent prognostic factors for OS. In total, 77 (61.1%) patients suffered from skin reactions and the incidence of grade 3-5 skin toxicity was 5.6% (7/126) | ||
| 520 | |a CONCLUSION: Radioactive Iodine-125 seed implantation seems efficient with acceptable toxicity for the treatment of lymph node recurrence secondary to esophageal cancer. A head-to-head study is needed to further evaluate the survival benefit | ||
| 650 | 4 | |a Multicenter Study | |
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a Esophageal cancer | |
| 650 | 4 | |a Prognosis | |
| 650 | 4 | |a Radioactive Iodine-125 seed | |
| 650 | 4 | |a Radiotherapy | |
| 650 | 4 | |a Toxicity | |
| 650 | 7 | |a Iodine-125 |2 NLM | |
| 650 | 7 | |a GVO776611R |2 NLM | |
| 650 | 7 | |a Iodine Radioisotopes |2 NLM | |
| 700 | 1 | |a Zhao, Xinxin |e verfasserin |4 aut | |
| 700 | 1 | |a Tian, Suqing |e verfasserin |4 aut | |
| 700 | 1 | |a Zhang, Kaixian |e verfasserin |4 aut | |
| 700 | 1 | |a He, Chuang |e verfasserin |4 aut | |
| 700 | 1 | |a Feng, Yong |e verfasserin |4 aut | |
| 700 | 1 | |a Zhou, Jiawei |e verfasserin |4 aut | |
| 700 | 1 | |a Guo, Wenjie |e verfasserin |4 aut | |
| 700 | 1 | |a Ji, Zhe |e verfasserin |4 aut | |
| 700 | 1 | |a He, Xia |e verfasserin |4 aut | |
| 700 | 1 | |a Chen, Guanglie |e verfasserin |4 aut | |
| 700 | 1 | |a Wang, Junjie |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Radiation oncology (London, England) |d 2006 |g 18(2023), 1 vom: 26. Jan., Seite 18 |w (DE-627)NLM163016356 |x 1748-717X |7 nnns |
| 773 | 1 | 8 | |g volume:18 |g year:2023 |g number:1 |g day:26 |g month:01 |g pages:18 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1186/s13014-022-02196-y |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 18 |j 2023 |e 1 |b 26 |c 01 |h 18 | ||